SCHEMBL2961241

SCHEMBL2961241

C=CC(=O)N1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3CC)CC1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 0.78
▸ DRD3 P35462 1/20 0.76
▸ MEN1 O00255 7/20 0.73
▸ KMT2A Q03164 7/20 0.73
▸ KDM4E B2RXH2 8/20 0.71
▸ ALDH1A1 P00352 5/20 0.71
▸ HTT P42858 4/20 0.71
▸ HPGD P15428 3/20 0.71
▸ LMNA P02545 3/20 0.71
▸ TSHR P16473 2/20 0.71
▸ BRD4 O60885 1/20 0.71
▸ CYP2J2 P51589 1/20 0.71
▸ NPSR1 Q6W5P4 1/20 0.71
▸ HIF1A Q16665 1/20 0.70
▸ NPC1 O15118 1/20 0.69
▸ USP2 O75604 1/20 0.69
▸ SMN1; SMN2 Q16637 1/20 0.69
▸ PIK3CD O00329 3/20 0.66
▸ PIK3R1 P27986 3/20 0.66
▸ PIK3CA P42336 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10359316 0.90 HSD17B10 (0.75) HSD17B10DRD3MEN1KMT2AKDM4E
SCHEMBL10359317 0.90 HSD17B10 (0.75) HSD17B10DRD3MEN1KMT2AKDM4E
SCHEMBL22698592 0.90 HSD17B10 (0.84) HSD17B10DRD3MEN1KMT2AKDM4E
4-N-Acetyl-1-Piperazinyl-Norfloxacin SCHEMBL11027379 0.89 HSD17B10 (0.83) HSD17B10DRD3MEN1KMT2AKDM4E
4-N-Acetyl-1-Piperazinyl-Norfloxacin SCHEMBL30570718 0.89 HSD17B10 (0.83) HSD17B10DRD3MEN1KMT2AKDM4E
SCHEMBL6297413 0.88 HSD17B10 (0.81) HSD17B10DRD3MEN1KMT2AKDM4E
SCHEMBL11388509 0.87 DRD3 (0.74) HSD17B10DRD3MEN1KMT2AKDM4E
SCHEMBL6720826 0.87 HSD17B10 (0.80) HSD17B10DRD3MEN1KMT2AKDM4E
Pefloxacin SCHEMBL34292 0.86 DRD3 (1.00) HSD17B10DRD3MEN1KMT2AKDM4E
SCHEMBL10738656 0.86 DRD3 (0.84) HSD17B10DRD3MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188655-A1 Monomer With Anti-Microbial Character, Polymer Using The Same, And Manufacturing Method Thereof MICRO SCIENCE TECH CO., LTD. (KR) 2008-08-07 — — US claimed
US-7777033-B2 Monomer with anti-microbial character, polymer using the same, and manufacturing method thereof MICRO SCIENCE TECH CO., LTD. (KR) 2010-08-17 — — US disclosed
US-20080188655-A1 Monomer With Anti-Microbial Character, Polymer Using The Same, And Manufacturing Method Thereof MICRO SCIENCE TECH CO., LTD. (KR) 2008-08-07 — — US disclosed
US-7361719-B2 Monomer with anti-microbial character, polymer using the same, and manufacturing method thereof MICRO SCIENCE TECH CO., LTD. (KR) 2008-04-22 — — US disclosed
US-20050176905-A1 Monomer with anti-microbial character, polymer using the same, and manufacturing method thereof MICRO SCIENCE TECH CO., LTD. (KR) 2005-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188655-A1 Monomer With Anti-Microbial Character, Polymer Using The Same, And Manufacturing Method Thereof PCNA, HSF1, TERB1 HSD17B10 2090/4885DRD3 1287/4885MEN1 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback